Advanced

High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.

Ben Dror, Liv LU ; Gaber, Alexander LU ; Ulmert, David LU ; Uhlén, Mathias; Bjartell, Anders LU and Jirström, Karin LU (2011) In Diagnostic Pathology 6.
Abstract
BACKGROUND:



High expression of the RNA-binding protein RBM3 has previously been found to be associated with good prognosis in breast cancer, ovarian cancer, malignant melanoma and colorectal cancer. The aim of this study was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer.

FINDINGS:



Immunohistochemical RBM3 expression was examined in a tissue microarray with malignant and benign prostatic specimens from 88 patients treated with radical prostatectomy for localized disease. While rarely expressed in benign prostate gland epithelium, RBM3 was found to be up-regulated in prostate intraepithelial neoplasia and present in various fractions and intensities... (More)
BACKGROUND:



High expression of the RNA-binding protein RBM3 has previously been found to be associated with good prognosis in breast cancer, ovarian cancer, malignant melanoma and colorectal cancer. The aim of this study was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer.

FINDINGS:



Immunohistochemical RBM3 expression was examined in a tissue microarray with malignant and benign prostatic specimens from 88 patients treated with radical prostatectomy for localized disease. While rarely expressed in benign prostate gland epithelium, RBM3 was found to be up-regulated in prostate intraepithelial neoplasia and present in various fractions and intensities in invasive prostate cancer. High nuclear RBM3 expression was significantly associated with a prolonged time to biochemical recurrence (BCR) (HR 0.56, 95% CI: 0.34-0.93, p = 0.024) and clinical progression (HR 0.09, 95% CI: 0.01-0.71, p = 0.021). These associations remained significant in multivariate analysis, adjusted for preoperative PSA level in blood, pathological Gleason score and presence or absence of extracapsular extension, seminal vesicle invasion and positive surgical margin (HR 0.41, 95% CI: 0.19-0.89, p = 0.024 for BCR and HR 0.06, 95% CI: 0.01-0.50, p = 0.009 for clinical progression).

CONCLUSION:



Our results demonstrate that high nuclear expression of RBM3 in prostate cancer is associated with a prolonged time to disease progression and, thus, a potential biomarker of favourable prognosis. The value of RBM3 for prognostication, treatment stratification and follow-up of prostate cancer patients should be further validated in larger studies. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diagnostic Pathology
volume
6
publisher
BioMed Central
external identifiers
  • wos:000295922500001
  • pmid:21955582
  • scopus:80053380290
ISSN
1746-1596
DOI
10.1186/1746-1596-6-91
language
English
LU publication?
yes
id
ac0969fc-9bc3-4a8e-a6a2-c4aea65712c9 (old id 2201075)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21955582?dopt=Abstract
date added to LUP
2011-11-01 13:06:01
date last changed
2017-04-30 16:01:18
@article{ac0969fc-9bc3-4a8e-a6a2-c4aea65712c9,
  abstract     = {BACKGROUND:<br/><br>
<br/><br>
High expression of the RNA-binding protein RBM3 has previously been found to be associated with good prognosis in breast cancer, ovarian cancer, malignant melanoma and colorectal cancer. The aim of this study was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer.<br/><br>
FINDINGS:<br/><br>
<br/><br>
Immunohistochemical RBM3 expression was examined in a tissue microarray with malignant and benign prostatic specimens from 88 patients treated with radical prostatectomy for localized disease. While rarely expressed in benign prostate gland epithelium, RBM3 was found to be up-regulated in prostate intraepithelial neoplasia and present in various fractions and intensities in invasive prostate cancer. High nuclear RBM3 expression was significantly associated with a prolonged time to biochemical recurrence (BCR) (HR 0.56, 95% CI: 0.34-0.93, p = 0.024) and clinical progression (HR 0.09, 95% CI: 0.01-0.71, p = 0.021). These associations remained significant in multivariate analysis, adjusted for preoperative PSA level in blood, pathological Gleason score and presence or absence of extracapsular extension, seminal vesicle invasion and positive surgical margin (HR 0.41, 95% CI: 0.19-0.89, p = 0.024 for BCR and HR 0.06, 95% CI: 0.01-0.50, p = 0.009 for clinical progression).<br/><br>
CONCLUSION:<br/><br>
<br/><br>
Our results demonstrate that high nuclear expression of RBM3 in prostate cancer is associated with a prolonged time to disease progression and, thus, a potential biomarker of favourable prognosis. The value of RBM3 for prognostication, treatment stratification and follow-up of prostate cancer patients should be further validated in larger studies.},
  articleno    = {91},
  author       = {Ben Dror, Liv and Gaber, Alexander and Ulmert, David and Uhlén, Mathias and Bjartell, Anders and Jirström, Karin},
  issn         = {1746-1596},
  language     = {eng},
  publisher    = {BioMed Central},
  series       = {Diagnostic Pathology},
  title        = {High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.},
  url          = {http://dx.doi.org/10.1186/1746-1596-6-91},
  volume       = {6},
  year         = {2011},
}